2444-054X

S2444-054X2025000100002

10.24875/ciru.24000209

P.R. China

00 02 2025

93 1 6 12

2020 41

1-24

2020 44

1564-76

2020 25

61-71

2020 60

381-9

2020 38

905-14

2019 25

349-56

2021 12

7003-9

2019 98

2021 12

803676

2019 69

197-215

2019 38

973-8

2023 44

1065-8

2019 364

l1049

Erratum to “Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%:the EMPOWER-Lung 1 study” 2024 130

1715

2023 41

914-30

2019 27

3105-18

2023 18

142

2021 15

231-9

2023 317

116751

2019 111

1376-82